CMHC 2015 Symposium: Diagnosis and Management Strategies for Lipodystrophy

Novel therapies, including the FDA-approved leptin replacement therapy, have been shown to reduce the metabolic consequences of some subtypes of lipodystrophy. This webcast, endorsed by Lipodystrophy United, is framed around case studies that introduce, highlight, and/or reinforce key presentation and discussion topics related to lipodystrophy, including its metabolic consequences and the impact of these consequences on long-term outcomes.

Supported by an educational grant from Aegerion Pharmaceuticals, Inc.
Endorsed by Lipodystrophy United.

Opening Remarks: Clinical Approaches and Considerations in the Detection and Diagnosis of Lipodystrophy

Chairperson: Abhimanyu Garg, MD

Clinical Updates on Lipodystrophy: Translating Research into Practice

Presenter: Vinaya Simha, MBBS, MD

Practical Management Considerations in Lipodystrophy

Presenter: Elaine K. Cochran, CRNP

Lessons from Misdiagnosed or Undiagnosed Cases: Common Pitfalls of Clinical Care

Presenter: Dwanna Swan, Ph.D.

Panel Discussion and Audience Question and Answer

Moderator: Abhimanyu Garg, MD

Discussants: Elaine K. Cochran, CRNPVinaya Simha, MBBS, MDDwanna Swan, Ph.D.